Ugur Sahin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7354462/publications.pdf

Version: 2024-02-01

201 papers	42,988 citations	12330 69 h-index	2895 190 g-index
219 all docs	219 docs citations	219 times ranked	45223 citing authors

#	Article	IF	Citations
1	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, 2022, 386, 35-46.	27.0	431
2	Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA. Pharmaceutics, 2022, 14, 328.	4.5	20
3	Identification of neoantigens for individualized therapeutic cancer vaccines. Nature Reviews Drug Discovery, 2022, 21, 261-282.	46.4	173
4	Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccineâ€“elicited human sera. Science, 2022, 375, 678-680.	12.6	303
5	An Fc-inert PD-L1Ã—4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation. OncoImmunology, 2022, 11, 2030135.	4.6	9
6	IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nature Immunology, 2022, 23, 532-542.	14.5	178
7	3D Melanoma Cocultures as Improved Models for Nanoparticle-Mediated Delivery of RNA to Tumors. Cells, 2022, 11, 1026.	4.1	4
8	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. MBio, 2022, 13, e0297921.	4.1	117
9	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. New England Journal of Medicine, 2022, 386, 1910-1921.	27.0	215
10	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine, 2022, 40, 1483-1492.	3.8	32
11	Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens. Nature Biotechnology, 2022, 40, 1276-1284.	17.5	25
12	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. Npj Vaccines, 2022, 7, 41.	6.0	4
13	Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1975-1988.	4.2	11
14	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discovery, 2022, 12, 1248-1265.	9.4	36
15	A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections. Molecular Therapy - Nucleic Acids, 2022, 28, 743-754.	5.1	9
16	Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Science Immunology, 2022, 7, .	11.9	144
17	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. Advances in Therapy, 2022, 39, 3789-3798.	2.9	3
18	Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerging Microbes and Infections, 2022, 11, 1828-1832.	6.5	32

#	Article	IF	Citations
19	Steatohepatitis Impairs T-cellâ€“Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6.	1.3	46
20	A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science, 2021, 371, 145-153.	12.6	253
21	Iodine-124 PET quantification of organ-specific delivery and expression of NIS-encoding RNA. EJNMMI Research, 2021, 11, 14.	2.5	3
22	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 2021, 592, 283-289.	27.8	494
23	Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+â€‰gastroesophageal adenocarcinoma. Gastric Cancer, 2021, 24, 721-730.	5.3	23
24	Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccineâ€“elicited human sera. Science, 2021, 371, 1152-1153.	12.6	485
25	Neutralizing Activity of BNT162b2-Elicited Serum. New England Journal of Medicine, 2021, 384, 1466-1468.	27.0	528
26	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nature Medicine, 2021, 27, 1062-1070.	30.7	114
27	BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19. Vaccines, 2021, 9, 324.	4.4	14
28	mRNA therapeutics in cancer immunotherapy. Molecular Cancer, 2021, 20, 69.	19.2	168
29	NeoFox: annotating neoantigen candidates with neoantigen features. Bioinformatics, 2021, 37, 4246-4247.	4.1	11
30	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature, 2021, 595, 572-577.	27.8	583
31	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature, 2021, 596, 273-275.	27.8	318
32	Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient. International Journal of Molecular Sciences, 2021, 22, 7583.	4.1	3
33	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. New England Journal of Medicine, 2021, 385, 472-474.	27.0	93
34	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New England Journal of Medicine, 2021, 385, 239-250.	27.0	709
35	Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Science Translational Medicine, 2021, 13, eabc7804.	12.4	79
36	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. New England Journal of Medicine, 2021, 385, 1627-1629.	27.0	346

#	Article	IF	Citations
37	Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates. PLoS ONE, 2021, 16, e0249254.	2.5	31
38	Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. PLoS ONE, 2021, 16, e0255580.	2.5	6
39	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 2021, 385, 1761-1773.	27.0	1,090
40	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nature Communications, 2021, 12, 7105.	12.8	22
41	ArtiFuseâ€"computational validation of fusion gene detection tools without relying on simulated reads. Bioinformatics, 2020, 36, 373-379.	4.1	3
42	A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Molecular Therapy, 2020, 28, 119-128.	8.2	99
43	An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science, 2020, 367, 446-453.	12.6	286
44	Prognostic Significance of Interferon-Î³ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes. International Journal of Molecular Sciences, 2020, 21, 7178.	4.1	17
45	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 2020, 586, 594-599.	27.8	1,520
46	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	27.0	2,107
47	PhaseÂI/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 2020, 586, 589-593.	27.8	1,197
48	A liposomal RNA vaccine inducing neoantigen-specific CD4 ⁺ T cells augments the antitumor activity of local radiotherapy in mice. OncoImmunology, 2020, 9, 1771925.	4.6	32
49	Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. Frontiers in Oncology, 2020, 10, 1195.	2.8	94
50	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585, 107-112.	27.8	526
51	Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. Langmuir, 2020, 36, 13331-13341.	3.5	28
52	Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Applied Nano Materials, 2020, 3, 10634-10645.	5.0	108
53	Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA. Cells, 2020, 9, 2034.	4.1	57
54	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 2020, 383, 2603-2615.	27.0	11,472

#	Article	IF	Citations
55	Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. OncoImmunology, 2020, 9, 1758004.	4.6	17
56	Personalized Neo-Epitope Vaccines for Cancer Treatment. Recent Results in Cancer Research, 2020, 214, 153-167.	1.8	9
57	Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors. , 2020, , .		18
58	Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Advances, 2020, 4, 5702-5715.	5.2	24
59	PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation. Oncotarget, 2020, 11, 1862-1875.	1.8	7
60	Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Research, 2020, 80, CT301-CT301.	0.9	31
61	Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy. BMC Cancer, 2019, 19, 694.	2.6	11
62	HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. OncoImmunology, 2019, 8, e1629259.	4.6	58
63	Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. Annual Review of Medicine, 2019, 70, 395-407.	12.2	54
64	Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 870-876.	1.3	64
65	Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. OncoImmunology, 2019, 8, e1601480.	4.6	18
66	A Facile Method for the Removal of dsRNA Contaminant from InÂVitro-Transcribed mRNA. Molecular Therapy - Nucleic Acids, 2019, 15, 26-35.	5.1	271
67	Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. Molecular Therapy - Methods and Clinical Development, 2019, 12, 32-46.	4.1	74
68	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
69	A non-functional neoepitope specific CD8⁺ T-cell response induced by tumor derived antigen exposure in vivo. OncoImmunology, 2019, 8, 1553478.	4.6	16
70	Characterization of zolbetuximab in pancreatic cancer models. OncoImmunology, 2019, 8, e1523096.	4.6	52
71	Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3â€² UTRs Identified by Cellular Library Screening. Molecular Therapy, 2019, 27, 824-836.	8.2	191
72	Transferring a Quantitative Molecular Diagnostic Test to Multiple Real-Time Quantitative PCR Platforms. Journal of Molecular Diagnostics, 2018, 20, 398-414.	2.8	7

#	Article	IF	Citations
73	Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Molecular Therapy, 2018, 26, 446-455.	8.2	315
74	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Research, 2018, 20, 15.	5.0	71
75	Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide. Journal of Nanobiotechnology, 2018, 16, 39.	9.1	23
76	Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance. Journal of Immunological Methods, 2018, 458, 74-82.	1.4	5
77	Personalized vaccines for cancer immunotherapy. Science, 2018, 359, 1355-1360.	12.6	697
78	Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration. Molecular Pharmaceutics, 2018, 15, 642-651.	4.6	23
79	Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells. OncoImmunology, 2018, 7, e1409929.	4.6	26
80	Displaying Tetraâ€Membrane Spanning Claudins on Enveloped Virusâ€Like Particles for Cancer Immunotherapy. Biotechnology Journal, 2018, 13, e1700345.	3.5	13
81	In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI Research, 2018, 8, 80.	2.5	28
82	Induction of immunosuppressive functions and NF-ÎºB by FLIP in monocytes. Nature Communications, 2018, 9, 5193.	12.8	45
83	Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Diagnostic Pathology, 2018, 13, 83.	2.0	2
84	Studying Tumor-ReacTive T Cells: A Personalized Organoid Model. Cell Stem Cell, 2018, 23, 318-319.	11.1	10
85	An RNA toolbox for cancer immunotherapy. Nature Reviews Drug Discovery, 2018, 17, 751-767.	46.4	171
86	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discovery, 2018, 8, 1366-1375.	9.4	80
87	A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. European Journal of Cancer, 2018, 100, 17-26.	2.8	85
88	Challenges towards the realization of individualized cancer vaccines. Nature Biomedical Engineering, 2018, 2, 566-569.	22.5	40
89	Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice. Molecular Pharmaceutics, 2018, 15, 3909-3919.	4.6	27
90	HLA and proteasome expression body map. BMC Medical Genomics, 2018, 11, 36.	1.5	95

#	Article	IF	Citations
91	In Silico Typing of Classical and Non-classical HLA Alleles from Standard RNA-Seq Reads. Methods in Molecular Biology, 2018, 1802, 177-191.	0.9	6
92	Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nature Medicine, 2017, 23, 815-817.	30.7	182
93	The European Regulatory Environment of RNA-Based Vaccines. Methods in Molecular Biology, 2017, 1499, 203-222.	0.9	22
94	Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. Methods in Molecular Biology, 2017, 1499, 223-236.	0.9	9
95	Improvement ofIn VivoExpression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins. Human Gene Therapy, 2017, 28, 1138-1146.	2.7	43
96	Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. Scientific Reports, 2017, 7, 16892.	3.3	23
97	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyperÂ®. Breast Cancer Research, 2017, 19, 55.	5.0	29
98	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 547, 222-226.	27.8	1,806
99	Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity. Journal of Immunology Research, 2016, 2016, 1-13.	2.2	7
100	Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer, 2016, 16, 398.	2.6	44
101	FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines. Methods in Molecular Biology, 2016, 1428, 163-175.	0.9	9
102	Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Research and Treatment, 2016, 157, 437-446.	2.5	33
103	Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. Clinical Cancer Research, 2016, 22, 1885-1896.	7.0	128
104	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. Clinical Cancer Research, 2016, 22, 4827-4836.	7.0	24
105	Past, present and future of immunology in Mainz. Cellular Immunology, 2016, 308, 1-6.	3.0	0
106	Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. Nanomedicine, 2016, 11, 2723-2734.	3.3	82
107	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology, 2016, 5, e1240859.	4.6	75
108	Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential. Nucleic Acids Research, 2016, 44, gkw896.	14.5	52

#	Article	IF	Citations
109	Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunology, Immunotherapy, 2016, 65, 1075-1083.	4.2	59
110	NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nature Communications, 2016, 7, 11724.	12.8	46
111	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016, 534, 396-401.	27.8	1,243
112	Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. OncoImmunology, 2016, 5, e1091555.	4.6	39
113	Mutanome directed cancer immunotherapy. Current Opinion in Immunology, 2016, 39, 14-22.	5.5	55
114	Chromatin Immunoprecipitation Assay to Identify Genomic Binding Sites of Regulatory Factors. Methods in Molecular Biology, 2016, 1366, 53-65.	0.9	3
115	FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, LBA4001-LBA4001.	1.6	27
116	An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. Oncotarget, 2016, 7, 21199-21221.	1.8	32
117	TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Medicine, 2015, 7, 118.	8.2	78
118	Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdisciplinary Reviews RNA, 2015, 6, 471-499.	6.4	65
119	CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. Oncotarget, 2015, 6, 25356-25367.	1.8	40
120	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. Journal of Immunology Research, 2015, 2015, 1-6.	2.2	27
121	Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format. Progress in Tumor Research, 2015, 42, 44-54.	0.1	6
122	Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials, 2015, 49, 125-134.	11.4	53
123	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 2015, 520, 692-696.	27.8	1,030
124	Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays. Journal of Immunology, 2015, 194, 6177-6189.	0.8	9
125	Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies. OncoImmunology, 2015, 4, e1005523.	4.6	2
126	Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE). Lung Cancer, 2015, 90, 334-341.	2.0	26

#	Article	IF	Citations
127	A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. Journal of Virology, 2015, 89, 11654-11667.	3.4	108
128	Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. Human Gene Therapy, 2015, 26, 751-766.	2.7	61
129	In Silico HLA Typing Using Standard RNA-Seq Sequence Reads. Methods in Molecular Biology, 2015, 1310, 247-258.	0.9	13
130	Abstract P5-10-13: Low influence of tumor cell content on mRNA expression levels of ESR, PGR, HER2 and KI67 when performing the MammaTyperÂ® RT-PCR kit. , 2015, , .		1
131	Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes. Nucleic Acids Research, 2014, 42, 10245-10264.	14.5	49
132	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics, 2014, 15, 190.	2.8	334
133	Aberrantly activated claudin 6 and 18.2 as potential therapy targets in nonâ€smallâ€cell lung cancer. International Journal of Cancer, 2014, 135, 2206-2214.	5.1	82
134	Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362. Biotechnology Journal, 2014, 9, 545-554.	3.5	6
135	A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. OncoImmunology, 2014, 3, e954893.	4.6	92
136	Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. International Journal of Cancer, 2014, 134, 731-739.	5.1	67
137	NFâ€ÎºB factors control the induction of NFATc1 in B lymphocytes. European Journal of Immunology, 2014, 44, 3392-3402.	2.9	16
138	mRNA-based therapeutics â€" developing a new class of drugs. Nature Reviews Drug Discovery, 2014, 13, 759-780.	46.4	1,501
139	Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes. Cancer Immunology Research, 2014, 2, 1230-1244.	3.4	35
140	The Wnt/Î²-Catenin Pathway Attenuates Experimental Allergic Airway Disease. Journal of Immunology, 2014, 193, 485-495.	0.8	47
141	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	27.8	613
142	Mutated tumor alleles are expressed according to their DNA frequency. Scientific Reports, 2014, 4, 4743.	3.3	40
143	A first-in-human dose escalation and dose-finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer (GM-IMAB-002-01).. Journal of Clinical Oncology, 2014, 32, TPS5623-TPS5623.	1.6	3
144	Antigen Identification Using SEREX. Methods in Molecular Biology, 2013, 1061, 59-77.	0.9	6

#	Article	IF	Citations
145	The regulatory landscape for actively personalized cancer immunotherapies. Nature Biotechnology, 2013, 31, 880-882.	17.5	62
146	NCOA3 is a selective co-activator of estrogen receptor Î±-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC Cancer, 2013, 13, 570.	2.6	21
147	The synthesis of isopropylidene mRNA cap analogs modified with phosphorothioate moiety and their evaluation as promoters of mRNA translation. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3753-3758.	2.2	25
148	Synthetic mRNAs with Superior Translation and Stability Properties. Methods in Molecular Biology, 2013, 969, 55-72.	0.9	44
149	Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro and In Vivo Preclinical Studies. Methods in Molecular Biology, 2013, 969, 235-246.	0.9	17
150	mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA. Cancer Immunology Research, 2013, 1, 386-392.	3.4	37
151	Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.. Journal of Clinical Oncology, 2013, 31, 4080-4080.	1.6	9
152	Confidence-based Somatic Mutation Evaluation and Prioritization. PLoS Computational Biology, 2012, 8, e1002714.	3.2	30
153	Exploiting the Mutanome for Tumor Vaccination. Cancer Research, 2012, 72, 1081-1091.	0.9	706
154	mRNA as a Versatile Tool for Exogenous Protein Expression. Current Gene Therapy, 2012, 12, 347-361.	2.0	57
155	A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin Îº C as a Compatible Prognostic Marker in Human Solid Tumors. Clinical Cancer Research, 2012, 18, 2695-2703.	7.0	237
156	Targeting the tumor mutanome for personalized vaccination therapy. OncoImmunology, 2012, 1, 768-769.	4.6	55
157	HLA typing from RNA-Seq sequence reads. Genome Medicine, 2012, 4, 102.	8.2	204
158	Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene, 2011, 481, 83-92.	2.2	63
159	FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines. Cancer Research, 2011, 71, 6132-6142.	0.9	70
160	Tumor vaccination using messenger RNA: prospects of a future therapy. Current Opinion in Immunology, 2011, 23, 399-406.	5.5	114
161	Highly Specific Auto-Antibodies against Claudin-18 Isoform 2 Induced by a Chimeric HBcAg Virus-Like Particle Vaccine Kill Tumor Cells and Inhibit the Growth of Lung Metastases. Cancer Research, 2011, 71, 516-527.	0.9	45
162	Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. RNA Biology, 2011, 8, 35-43.	3.1	32

#	Article	IF	Citations
163	Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity. Cancer Research, 2010, 70, 9031-9040.	0.9	253
164	Selective Activation of Trophoblast-specific PLAC1 in Breast Cancer by CCAAT/Enhancer-binding Protein Î² (C/EBPÎ²) Isoform 2. Journal of Biological Chemistry, 2009, 284, 28607-28615.	3.4	30
165	Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2. Molecular Cancer, 2009, 8, 77.	19.2	21
166	In silico strategy for detection of target candidates for antibody therapy of solid tumors. Gene, 2008, 414, 76-84.	2.2	2
167	MS4A12 Is a Colon-Selective Store-Operated Calcium Channel Promoting Malignant Cell Processes. Cancer Research, 2008, 68, 3458-3466.	0.9	58
168	Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals. Journal of Immunology, 2008, 180, 309-318.	0.8	141
169	Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clinical Cancer Research, 2008, 14, 7624-7634.	7.0	247
170	A Placenta-Specific Gene Ectopically Activated in Many Human Cancers Is Essentially Involved in Malignant Cell Processes. Cancer Research, 2007, 67, 9528-9534.	0.9	82
171	Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunology, Immunotherapy, 2007, 56, 1577-1587.	4.2	46
172	Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Letters, 2006, 236, 64-71.	7.2	71
173	Identification of new claudin family members by a novel PSI-BLAST based approach with enhanced specificity. Proteins: Structure, Function and Bioinformatics, 2006, 65, 808-815.	2.6	19
174	Expression profiling of autoimmune regulator AIRE mRNA in a comprehensive set of human normal and neoplastic tissues. Immunology Letters, 2006, 106, 172-179.	2.5	31
175	Rapid molecular dissection of viral and bacterial immunomes. European Journal of Immunology, 2006, 36, 1049-1057.	2.9	11
176	Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. International Journal of Cancer, 2006, 118, 2522-2528.	5.1	47
177	The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes. Human Molecular Genetics, 2006, 15, 2392-2399.	2.9	24
178	Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood, 2006, 108, 4009-4017.	1.4	457
179	Identification of Tumor-Associated Autoantigens With SEREX. , 2005, 109, 137-154.		24
180	Molecular Characterization of Virus-induced Autoantibody Responses. Journal of Experimental Medicine, 2004, 200, 637-646.	8.5	40

#	Article	IF	Citations
181	Frequent Nonrandom Activation of Germ-Line Genes in Human Cancer. Cancer Research, 2004, 64, 5988-5993.	0.9	45
182	CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein. Journal of Immunological Methods, 2004, 289, 191-199.	1.4	14
183	SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. Journal of Immunological Methods, 2003, 283, 261-267.	1.4	23
184	Expression of serologically identified tumor antigens in acute leukemias. Leukemia Research, 2003, 27, 655-660.	0.8	37
185	Autoimmunity seen through the SEREX-scope. Autoimmunity Reviews, 2003, 2, 339-345.	5.8	16
186	Computational dissection of tissue contamination for identification of colon cancerâ€specific expression profiles. FASEB Journal, 2003, 17, 376-385.	0.5	40
187	Cascades of transcriptional induction during dendritic cell maturation revealed by genomeâ€wide expression analysis. FASEB Journal, 2003, 17, 836-847.	0.5	79
188	Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma. Journal of Immunology, 2002, 168, 1717-1722.	0.8	106
189	A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene, 2002, 21, 3879-3888.	5.9	43
190	Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Research, 2002, 62, 6750-5.	0.9	84
191	Recognition of human tumors: SEREX expression cloning to identify tumour antigens. , 2001, , 45-57.		4
192	Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nature Biotechnology, 1999, 17, 555-561.	17.5	703
193	Expression ofSSX genes in human tumors. , 1998, 77, 19-23.		143
194	Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. , 1998, 78, 387-389.		99
195	Identification of Human Tumor Antigens Using the B-Cell Repertoire. , 1998, , 185-198.		1
196	Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease. Journal of Biological Chemistry, 1997, 272, 6416-6422.	3.4	223
197	Serological analysis of human tumor antigens: molecular definition and implications. Trends in Molecular Medicine, 1997, 3, 342-349.	2.6	185
198	Serological identification of human tumor antigens. Current Opinion in Immunology, 1997, 9, 709-716.	5.5	292

#	Article	IF	Citations
199	SSX: A multigene family with several members transcribed in normal testis and human cancer. International Journal of Cancer, 1997, 72, 965-971.	5.1	190
200	The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. European Journal of Immunology, 1995, 25, 2027-2033.	2.9	40
201	CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of hodgkin's lymphoma. International Journal of Cancer, 1993, 54, 820-827.	5.1	32